EA201691567A1 - Способы лечения легких травм головного мозга - Google Patents

Способы лечения легких травм головного мозга

Info

Publication number
EA201691567A1
EA201691567A1 EA201691567A EA201691567A EA201691567A1 EA 201691567 A1 EA201691567 A1 EA 201691567A1 EA 201691567 A EA201691567 A EA 201691567A EA 201691567 A EA201691567 A EA 201691567A EA 201691567 A1 EA201691567 A1 EA 201691567A1
Authority
EA
Eurasian Patent Office
Prior art keywords
brain
methods
treating pulmonary
pulmonary injuries
injuries
Prior art date
Application number
EA201691567A
Other languages
English (en)
Other versions
EA039367B1 (ru
Inventor
Вишал Бансал
Original Assignee
Те Риджентс Оф Те Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Те Риджентс Оф Те Юниверсити Оф Калифорния filed Critical Те Риджентс Оф Те Юниверсити Оф Калифорния
Publication of EA201691567A1 publication Critical patent/EA201691567A1/ru
Publication of EA039367B1 publication Critical patent/EA039367B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В настоящем изобретении представлены способы лечения легких травм головного мозга и других неврологических расстройств у пациентов, которые включают введение пациенту эффективного количества композиции, содержащей грелин.
EA201691567A 2014-02-05 2015-02-05 Способы лечения легких травм головного мозга с помощью грелина EA039367B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461936143P 2014-02-05 2014-02-05
US14/486,636 US9119832B2 (en) 2014-02-05 2014-09-15 Methods of treating mild brain injury
PCT/US2015/014692 WO2015120203A1 (en) 2014-02-05 2015-02-05 Methods of treating mild brain injury

Publications (2)

Publication Number Publication Date
EA201691567A1 true EA201691567A1 (ru) 2017-04-28
EA039367B1 EA039367B1 (ru) 2022-01-19

Family

ID=53753927

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691567A EA039367B1 (ru) 2014-02-05 2015-02-05 Способы лечения легких травм головного мозга с помощью грелина

Country Status (14)

Country Link
US (5) US9119832B2 (ru)
EP (1) EP3102226B1 (ru)
JP (1) JP6675315B2 (ru)
KR (1) KR102354384B1 (ru)
AU (1) AU2015214028B2 (ru)
BR (1) BR112016017886A8 (ru)
CA (1) CA2945487C (ru)
DK (1) DK3102226T3 (ru)
EA (1) EA039367B1 (ru)
ES (1) ES2714911T3 (ru)
IL (2) IL246957B (ru)
MX (1) MX2016010085A (ru)
NZ (1) NZ722600A (ru)
WO (1) WO2015120203A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
CA2961889A1 (en) * 2014-08-19 2016-02-25 Oxeia Biopharmaceuticals, Inc. Methods of treating mild brain injury
EP3197482A4 (en) * 2014-09-25 2018-04-25 Oxeia Biopharmaceuticals Inc. Methods of treating traumatic brain injury
WO2017075535A1 (en) * 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
US20210161926A1 (en) * 2018-08-08 2021-06-03 Neuro Biofuels Limited Methods for Treatment of Brain Injury and Brain Dysfunction
US20230031262A1 (en) * 2019-12-23 2023-02-02 Oxeia Biopharmaceuticals, Inc. Treatment of mild traumatic brain injury
CN111666409B (zh) * 2020-05-28 2022-02-08 武汉大学 一种基于综合深度胶囊网络的复杂评论文本的整体情感智能分类方法
WO2024054875A2 (en) * 2022-09-07 2024-03-14 Oxeia Biopharmaceuticals, Inc. Treatment of mild traumatic brain injury

Family Cites Families (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
DE2122529A1 (de) 1971-05-06 1972-12-14 Max Planck Gesellschaft zur Förde rung der Wissenschaften e V , 3400 Gottin gen Thiophosphatanaloge der Nucleosid di und tnphosphate sowie Verfahren zu ihrer Herstellung
US4228158A (en) 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228157A (en) 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4224316A (en) 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228156A (en) 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223019A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223021A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228155A (en) 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223020A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4226857A (en) 1979-03-30 1980-10-07 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4410513A (en) 1981-12-28 1983-10-18 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
WO1983002272A1 (en) 1981-12-28 1983-07-07 Beckman Instruments Inc Synthetic peptides having pituitary growth hormone releasing activity
US4410512A (en) 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
US5416073A (en) 1983-08-10 1995-05-16 The Adminstrators Of The Tulane Educational Fund Growth hormone-releasing peptides and method of treating animals, therewith
US4485101A (en) 1983-10-11 1984-11-27 Administrators Of The Tulane Educational Fund Peptides
US4650787A (en) 1985-04-25 1987-03-17 Schally Andrew Victor Biologically active octapeptides
DE3642648A1 (de) 1986-12-13 1988-06-23 Boehringer Ingelheim Kg Verwendung von 6-allyl-2-amino-5,6,7,8-tetrahydro-4h-thiazolo-(5,4-d)azepin zur freisetzung von wachstumshormon
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US4880777A (en) 1987-09-01 1989-11-14 Eastman Kodak Company Synthetic peptides having growth hormone releasing activity
AU637316B2 (en) 1988-01-28 1993-05-27 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
WO1989007111A1 (en) 1988-01-28 1989-08-10 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
DE68912775T2 (de) 1988-05-11 1994-06-30 Polygen Holding Corp Polypeptid-verbindungen mit hormonwachstumsbefreiender wirkung.
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US5668254A (en) 1990-05-11 1997-09-16 Romano Deghenghi D-2-alkyl-tryptophan and peptides containing same
US5872100A (en) 1990-05-11 1999-02-16 Deghenghi; Romano Peptides containing D-2-Alkyl-Tryptophan
US5486505A (en) 1990-07-24 1996-01-23 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
IL98910A0 (en) 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5206235A (en) 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
DE69231467T2 (de) 1991-05-10 2001-01-25 Genentech Inc Auswählen von agonisten und antagonisten von liganden
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5576301A (en) 1991-11-27 1996-11-19 The Penn State Research Foundation Low molecular growth potentiating peptides
US5283241A (en) 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5583130A (en) 1992-09-25 1996-12-10 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
WO1994007519A1 (en) 1992-09-25 1994-04-14 Smithkline Beecham Corporation Growth hormone releasing peptides
US5317017A (en) 1992-09-30 1994-05-31 Merck & Co., Inc. N-biphenyl-3-amido substituted benzolactams stimulate growth hormone release
US5374721A (en) 1992-10-14 1994-12-20 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
WO1994011012A1 (en) 1992-11-06 1994-05-26 Merck & Co., Inc. Substituted dipeptide analogs promote release of growth hormone
US5726319A (en) 1992-11-06 1998-03-10 Merck & Co., Inc. Biphenyl substituted dipeptide analogs promote release of growth hormone
WO1994011397A1 (en) 1992-11-13 1994-05-26 The Administrators Of The Tulane Educational Fund Ghrh agonists
RU2168512C2 (ru) 1992-12-11 2001-06-10 Мерк Энд Ко., Инк. Спиропиперидины, способы их получения (варианты)
US5536716A (en) 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
US5284841A (en) 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5434261A (en) 1993-07-26 1995-07-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5430144A (en) 1993-07-26 1995-07-04 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5691377A (en) 1993-07-30 1997-11-25 University Of Maryland Eastern Shore And University Of Maryland College Park Use of N-methyl-aspartic acid for enhancing growth and altering body composition
US5545735A (en) 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone
US5438136A (en) 1993-11-02 1995-08-01 Merck & Co., Inc. Benzo-fused macrocycles promote release of growth hormone
US5492916A (en) 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5492920A (en) 1993-12-10 1996-02-20 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
SK56296A3 (en) 1993-11-09 1997-02-05 Merck & Co Inc Piperidinal, pyrrolidinal and hexahydro-1h-azepinal derivatives, manufacturing process thereof and pharmaceutical compositions containing them
US5494919A (en) 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
EP0730578A4 (en) 1993-11-24 1997-10-08 Merck & Co Inc COMPOUNDS CONTAINING AN INDOLYL GROUP AND THEIR USE FOR PROMOTING THE RELEASE OF GROWTH HORMONES
US5721251A (en) 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
AU1371895A (en) 1993-12-13 1995-07-03 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5606054A (en) 1993-12-14 1997-02-25 Merck & Co., Inc. Heterocyclic-fused lactams promote release of growth hormone
US5550212A (en) 1993-12-17 1996-08-27 The Administrators Of The Tulane Educational Fund Analogues of hGH-RH(1-29)NH2 having antagonistic activity
IL112111A (en) 1993-12-23 2000-07-16 Novo Nordisk As Peptides having growth hormone releasing properties and pharmaceutical compositions containing them
US5721250A (en) 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
PL181280B1 (pl) 1993-12-23 2001-07-31 Novo Nordisk As oraz zawierajaca je kompozycja farmaceutyczna PL PL PL PL PL PL PL PL
US5579301A (en) 1994-02-28 1996-11-26 Micom Communications Corp. System for, and method of, managing voice congestion in a network environment
WO1995034311A1 (en) 1994-06-13 1995-12-21 Merck & Co., Inc. Piperazine compounds promote release of growth hormone
WO1996002530A1 (en) 1994-07-20 1996-02-01 Merck & Co., Inc. Piperidines and hexahydro-1h-azepines spiro substituted at the 4-position promote release of growth hormone
IL114955A (en) 1994-08-17 1999-12-22 Novo Nordisk As N-substituted naphthofused lactams and pharmaceutical compositions containing them
EP0783521B8 (en) 1994-09-27 2003-04-09 Ardana Bioscience Limited Polypeptide compounds containing d-2-alkyltryptophan capable of promoting the release of growth hormone
US5767118A (en) 1994-10-26 1998-06-16 Merck & Co., Inc. 4-Heterocyclic peperidines promote release of growth hormone
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
PL186511B1 (pl) 1995-01-27 2004-01-30 Novo Nordisk As Nowe związki peptydowe, kompozycje farmaceutycznedo pobudzania uwalniania hormonu wzrostu i zastosowanie tych związków do wytwarzania leku do pobudzania uwalniania hormonu wzrostu
AU4534696A (en) 1995-02-09 1996-08-27 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU4534596A (en) 1995-02-09 1996-08-27 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5656606A (en) 1995-02-17 1997-08-12 Merck & Co., Inc. Camphor compounds promote release of growth hormone
US5731317A (en) 1995-03-10 1998-03-24 Merck & Co., Inc. Bridged piperidines promote release of growth hormone
AU5441096A (en) 1995-04-14 1996-10-30 The Administrators Of The Tulane Eductional Fund Analogs of growth hormone-releasing factor
US5559128A (en) 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
WO1996033189A1 (en) 1995-04-19 1996-10-24 Merck & Co., Inc. Process for the preparation of spiroindolines
WO1996035713A1 (en) 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
DE69533991T2 (de) 1995-05-29 2006-04-13 Pfizer Inc. Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
IL122371A0 (en) 1995-06-22 1998-06-15 Novo Nordisk As Compounds with growth hormone releasing properties
AU6772996A (en) 1995-08-21 1997-03-12 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues
AU7169696A (en) 1995-09-26 1997-04-17 Merck & Co., Inc. 3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone
EP0857020A4 (en) 1995-10-27 1999-01-07 Merck & Co Inc FORMULATION OF SECRETAGOGUE STIMULATING THE SECRETION OF THE GROWTH HORMONE, INTENDED TO BE GRANULATED BY WET
SK51398A3 (en) 1995-10-27 1998-12-02 Merck & Co Inc Polymorphic forms of n-[1(r)-[(1,2-dihydro-1- -methanesulfonylspiro[3h-indole-3,4'-piperidin]-1'-yl)carbonyl]- -2-(phenylmethyloxy)ethyl]-2-amino-2-methyl-propanamide- -methanesulfonate, the preparation thereof, pharmaceutical composition containing them and their use
WO1997015573A1 (en) 1995-10-27 1997-05-01 Merck & Co., Inc. Process for the preparation of a growth hormone secretagogue
US5767124A (en) 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
SE9504019D0 (sv) 1995-11-13 1995-11-13 Pharmacia Ab Method for production of proteins
DE69633637T2 (de) 1995-12-13 2006-03-09 Merck & Co., Inc. Wachstumshormonsekretionsförderer rezeptorfamilie
WO1997022622A1 (en) 1995-12-15 1997-06-26 The Salk Institute For Biological Studies Betide-substituted gnrh antagonists
GB2308362A (en) 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
IT1277113B1 (it) 1995-12-20 1997-11-04 Romano Deghenghi Composti oligopeptidici contenenti d-2-alchiltriptofano in grado di promuovere la liberazione dell'ormone della crescita
WO1997022367A1 (en) 1995-12-20 1997-06-26 Merck & Co., Inc. Radiolabeled growth hormone secretagogue
EP0869974B1 (en) 1995-12-22 2009-03-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
CA2240685A1 (en) 1996-01-11 1997-07-17 Pharmacia & Upjohn Company Aqueous prolonged release formulation
FR2744123B1 (fr) 1996-01-26 1998-04-17 Carelli Claude Marcel Henri Molecules biologiquement actives plus particulierement peptidiques ayant un effet potentialisateur de l'activite biologique de l'hormone de croissance
AU2334097A (en) 1996-03-21 1997-10-10 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
US5837861A (en) 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5804578A (en) 1996-04-03 1998-09-08 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
AU2382097A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Compounds with growth hormone releasing properties
EP0907643B1 (en) 1996-04-24 2003-01-15 Novo Nordisk A/S Compounds with growth hormone releasing properties
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US5942489A (en) 1996-05-03 1999-08-24 The Administrators Of The Tulane Educational Fund HGH-RH(1-29)NH2 analogues having antagonistic activity
US5807985A (en) 1996-06-11 1998-09-15 Deghenghi; Romano Oligopeptide compounds containing D-2-alkyltryptophan capable of promoting the release of growth hormone
DE69734215T2 (de) 1996-07-22 2006-06-29 Novo Nordisk A/S Verbindungen mit Wachstumshormon-freisetzenden Eigenschaften
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
WO1998010653A1 (en) 1996-09-13 1998-03-19 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US5877182A (en) 1996-09-13 1999-03-02 Merck & Co., Inc. Piperidines promote release of growth hormone
WO1998016527A1 (en) 1996-10-15 1998-04-23 Fujisawa Pharmaceutical Co., Ltd. Benzoxepine derivatives which promote release of growth hormone
WO1998025622A1 (en) 1996-12-09 1998-06-18 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss
WO1998025897A1 (en) 1996-12-12 1998-06-18 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
AU6747498A (en) 1997-04-11 1998-11-11 Sumitomo Pharmaceuticals Company, Limited Benzene derivatives
WO1998046220A1 (en) 1997-04-14 1998-10-22 Merck & Co., Inc. Combination therapy for the prevention and treatment of osteoporosis
US6329368B1 (en) 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
WO1998051687A1 (en) 1997-05-14 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Piperidino derivatives which promote growth hormone release
AU7906998A (en) 1997-06-20 1999-01-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
EP1001970B1 (en) 1997-06-25 2007-03-07 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
UA64751C2 (ru) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Translated By PlajЛЕЧЕНИЕ ИНСУЛИНОВОЙ ТОЛЕРАНТНОСТИ ВЕЩЕСТВАМИ, КОТОРЫЕ УСИЛИВАЮТ СЕКРЕЦИЮ ГОРМОНА РОСТА
UA53716C2 (ru) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратная соль замещенного дипептида в качестве средства, стимулирующего секрецию гормона роста
ZA987385B (en) 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
WO1999009991A1 (en) 1997-08-22 1999-03-04 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives
ID29198A (id) 1997-08-29 2001-08-09 Univ North Carolina Pemakaian uridin 5'-difosfat dan persamaannya untuk mengobati penyakit paru-paru
AU5671099A (en) 1998-08-14 2000-03-06 The Administrators Of The Tulane Eductional Fund Compounds having growth hormone releasing activity
KR100699404B1 (ko) 1999-02-18 2007-03-23 가켄 세야쿠 가부시키가이샤 성장 호르몬 분비촉진제로서의 신규 아미드 유도체
DE60022683D1 (de) * 1999-12-28 2005-10-20 Kaken Pharma Co Ltd Nervenschutzmittel
CA2411667A1 (en) 2000-05-30 2001-12-06 Merck & Co. Inc. Ghrelin analogs
WO2002008250A2 (en) 2000-07-24 2002-01-31 Ardana Bioscience Limited Ghrelin antagonists
IL145106A0 (en) 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
WO2003049761A1 (en) 2000-12-08 2003-06-19 Neuronz Limited Use of insuline-like growth factor-i for promoting remyelination of axons
CU23157A1 (es) 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
EP1312363A1 (en) 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
US7937145B2 (en) 2002-03-22 2011-05-03 Advanced Neuromodulation Systems, Inc. Dynamic nerve stimulation employing frequency modulation
IL162796A0 (en) 2002-05-21 2005-11-20 Kenji Kangawa Medicinal compositions containing ghrelin
US20040081652A1 (en) 2002-07-15 2004-04-29 The Johns Hopkins University Neuronal and optic nerve gene expression patterns
RU2373220C2 (ru) 2002-07-23 2009-11-20 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик (С.К.Р.А.С.) Аналоги грелина
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
DK1633774T3 (da) 2003-06-18 2010-05-25 Tranzyme Pharma Inc Makrocykliske motilinreceptorantagonister
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7420587B2 (en) 2003-07-03 2008-09-02 Rufus Davis Apparatus and method for inspecting sewer lines using small mobile vehicles
DE602004018782D1 (de) 2003-07-31 2009-02-12 Tranzyme Pharma Inc Räumlich definierte makrocyclen, die peptidbindungssurrogate enthalten
DK1648922T3 (da) 2003-07-31 2011-03-14 Tranzyme Pharma Inc Rumligt definerede makrocykliske forbindelser, der er anvendelige til opdagelse af lægemidler
WO2005039625A1 (en) 2003-10-28 2005-05-06 Rheoscience A/S Growth hormone secretagogue receptor agonists
EP1529533A1 (en) 2003-11-06 2005-05-11 Sahltech I Göteborg AB Use of GH secretagogues in hypoxic-ischemic brain injury
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US8420602B2 (en) 2004-09-14 2013-04-16 Landon C. G. Miller Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders
WO2006045314A2 (en) 2004-10-27 2006-05-04 Gastrotech Pharma A/S Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease
WO2006079077A2 (en) 2005-01-20 2006-07-27 Acadia Pharmaceuticals Inc. Use of diltiazem or analogs thereof as modulators of ghrelin receptor
UY29460A1 (es) 2005-04-08 2006-11-30 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
WO2007044641A2 (en) 2005-10-06 2007-04-19 University Technologies International Inc. Glutathione peroxidase mimetics and uses thereof
GB0603295D0 (en) 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
CU23592A1 (es) 2006-02-28 2010-11-11 Ct Ingenieria Genetica Biotech Método para prevenir y eliminar las fibrosis y otras formas de depósito patológico en los tejidos aplicando el péptido secretagogo ghrp-6
BRPI0708895A2 (pt) 2006-03-13 2011-06-28 Liat Mintz uso de variante de junção de grelina para tratar caquexia e/ou anorexia e/ou anorexia-caquexia e/ou subnutrição e/ou lipodistrofia e/ou atrofia muscular e/ou estimulação do apetite
US7763707B2 (en) 2006-03-13 2010-07-27 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
BRPI0712607A8 (pt) 2006-05-25 2019-06-04 Biogen Idec Inc métodos de tratamento de acidente vascular cerebral
SI2029742T1 (sl) 2006-06-07 2016-11-30 Genzyme Corporation Genska terapija amiotrofične lateralne skleroze in drugih motenj hrbtenjače
EP2106275A2 (en) 2006-06-09 2009-10-07 Leptos Biomedical, Inc. Dynamic nerve stimulation employing frequency modulation
US8088733B2 (en) 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
JPWO2008018600A1 (ja) 2006-08-11 2010-01-07 国立大学法人 宮崎大学 グレリン及びその誘導体又はＧＨＳ−Ｒ１ａに作用する物質を有効成分とする脊髄神経修復促進治療剤
WO2008100629A2 (en) 2007-02-16 2008-08-21 Synvista Therapeutics, Inc. Glutathione peroxidase mimetics for the treatment of dermatoses
WO2008113072A2 (en) 2007-03-15 2008-09-18 Board Of Regents, The University Of Texas System Gpcr enhanced neuroprotection to treat brain injury
WO2008143835A1 (en) 2007-05-15 2008-11-27 Yale University Ghrelin protects substantia nigra dopamine neurons
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
US8324151B2 (en) 2007-11-20 2012-12-04 The Feinstein Institute For Medical Research Treatment of sepsis and septic shock using ghrelin and growth hormone
EP2067481A1 (en) 2007-12-03 2009-06-10 Charité-Universitätsmedizin Berlin Therapeutic use of desacyl ghrelin
KR100977625B1 (ko) 2008-01-08 2010-08-23 경희대학교 산학협력단 그렐린을 함유하는 척수 손상 치료용 약학적 조성물
CN102405043B (zh) 2009-01-09 2017-08-22 得克萨斯州大学***董事会 前神经原性化合物
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
MX362028B (es) 2009-02-03 2019-01-04 Amunix Pharmaceuticals Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
HUE062339T2 (hu) 2009-02-13 2023-10-28 Immunomedics Inc Sejten belül hasítható kötést tartalmazó immunkonjugátumok
US8883721B2 (en) 2009-05-12 2014-11-11 Mcgill University Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
SG193389A1 (en) 2011-03-10 2013-10-30 Xeris Pharmaceuticals Inc Stable formulations for parenteral injection of peptide drugs
US9376481B2 (en) 2011-04-26 2016-06-28 The Regents Of The University Of California Methods of promoting CNS neuronal repair by inhibiting LRP-1
US20120302526A1 (en) 2011-05-27 2012-11-29 Regents Of The University Of Colorado, A Body Corporate Methods for treating post-traumatic stress disorder
EP2723426B1 (en) 2011-06-21 2019-08-07 Brent Buchine Automatic mixing device and delivery system
CU23963B1 (es) 2011-07-01 2013-12-11 Ct De Ingeniería Genética Y Biotecnología Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas
AU2012310328A1 (en) 2011-09-23 2014-04-10 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Anti-Tumor Necrosis Factor-alpha agents and uses thereof
KR20140098741A (ko) 2011-10-07 2014-08-08 플로리다 스테이트 유니버시티 리서치 파운데이션, 인크 뇌진탕과 연관된 더 나은 결과에 대한 프로게스테론의 예방적 및 후-급성 용도
AR089860A1 (es) 2012-02-03 2014-09-24 Zealand Pharma As Analogos de la grelina
WO2013119650A1 (en) 2012-02-06 2013-08-15 Board Of Regents Of The University Of Nebraska Delivery of biotherapeutics to the brain
KR102057356B1 (ko) 2012-02-27 2019-12-18 아뮤닉스 파마슈티컬스, 인크. Ｘｔｅｎ 콘주게이트 조성물 및 그의 제조 방법
CN109999013A (zh) 2012-02-29 2019-07-12 普马特里克斯营业公司 可吸入干粉剂
US20140018299A1 (en) 2012-07-10 2014-01-16 Banyan Biomarkers, Inc. Method and device to detect, monitor and promote neural regeneration and improvement of cognitive function in a subject suffering from neural injury
US20140024053A1 (en) 2012-07-20 2014-01-23 Banyan Biomarkers, Inc. Methods, kits and devices for detecting bii-spectrin, and breakdown products thereof, as biomarkers for the diagnosis of neural injury
US20140255517A1 (en) 2013-03-06 2014-09-11 Emory University Managing post-traumatic stress disorder
EP2986113B1 (en) 2013-04-16 2020-08-26 The Children's Hospital of Philadelphia Compositions and methods for the treatment of brain injury
WO2015017123A1 (en) 2013-07-16 2015-02-05 Liat Mintz Ghrelin splice variant for treating neuronal damage,neurodegenerative disease, parkinsons disease, alzheimers disease, and/or depression
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
CA2961889A1 (en) 2014-08-19 2016-02-25 Oxeia Biopharmaceuticals, Inc. Methods of treating mild brain injury
EP3197482A4 (en) 2014-09-25 2018-04-25 Oxeia Biopharmaceuticals Inc. Methods of treating traumatic brain injury
WO2016134215A1 (en) 2015-02-19 2016-08-25 The Regents Of The University Of California Methods of treating mild brain injury and post-traumatic stress disorder

Also Published As

Publication number Publication date
US11241483B2 (en) 2022-02-08
EA039367B1 (ru) 2022-01-19
IL293712B1 (en) 2023-04-01
US10105416B2 (en) 2018-10-23
JP2017506625A (ja) 2017-03-09
US20220401520A1 (en) 2022-12-22
KR20160110520A (ko) 2016-09-21
CA2945487A1 (en) 2015-08-13
US9119832B2 (en) 2015-09-01
AU2015214028B2 (en) 2020-08-27
AU2015214028A1 (en) 2016-08-18
IL293712A (en) 2022-08-01
DK3102226T3 (en) 2019-03-25
EP3102226B1 (en) 2018-12-19
US10617740B2 (en) 2020-04-14
IL293712B2 (en) 2023-08-01
JP6675315B2 (ja) 2020-04-01
WO2015120203A1 (en) 2015-08-13
BR112016017886A8 (pt) 2018-04-17
IL246957B (en) 2022-07-01
US20160367637A1 (en) 2016-12-22
EP3102226A1 (en) 2016-12-14
MX2016010085A (es) 2016-11-15
KR102354384B1 (ko) 2022-01-21
ES2714911T3 (es) 2019-05-30
US20190216900A1 (en) 2019-07-18
US20210052702A1 (en) 2021-02-25
IL246957A0 (en) 2016-09-29
BR112016017886A2 (pt) 2017-10-10
CA2945487C (en) 2022-12-06
US20150216939A1 (en) 2015-08-06
NZ722600A (en) 2023-06-30

Similar Documents

Publication Publication Date Title
EA201691567A1 (ru) Способы лечения легких травм головного мозга
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
PH12019501339A1 (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
EA201790273A1 (ru) Флагеллиновые композиции и их применение
GB2541571A (en) Pharmaceutical compositions
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
PH12017500493A1 (en) Combination therapy
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
EA201692109A1 (ru) Варианты антител к фактору d и их применение
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
MX2016010328A (es) Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
NZ773981A (en) Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201792610A1 (ru) Способ лечения неврологического заболевания
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
TW201613569A (en) Composition consisting of kukoamine A and/or kukoamine B and method of using thereof
JO3609B1 (ar) علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
EA201691335A1 (ru) Гексагидрофуропирролы в качестве ингибиторов pde1